USPTO Nixes Apotex Bid for Plavix Patent Re-Exam
The U.S. Patent and Trademark Office has denied generic-drug maker Apotex Inc.'s second request for re-examination of the patent for blockbuster blood-thinning drug Plavix, in another boost for partners Bristol-Myers Squibb...To view the full article, register now.
Already a subscriber? Click here to view full article